☆ 4.8 Correction

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease (vol 537, pg 50, 2016)

NATURE (2017)

期刊

NATURE

卷 546, 期 7659, 页码 564-564

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/nature22809

关键词

-

类别

Multidisciplinary Sciences

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Neurosciences

Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease

Joakim Bastrup, Kathrine H. Hansen, Thomas B. G. Poulsen, Kenneth Kastaniegaard, Ayodeji A. Asuni, Soren Christensen, Dorthe Belling, Lone Helboe, Allan Stensballe, Christiane Volbracht

Summary: Chronic treatment with aducanumab significantly reduces the number of senile plaques in AD mouse model and alters the proteomic profile of surrounding tissue, potentially inhibiting Aβ toxicity and increase cell viability.

JOURNAL OF ALZHEIMERS DISEASE (2021)

添加到收藏夹

Article Neurosciences

Making the Case for Accelerated Withdrawal of Aducanumab

Peter Whitehouse, Sam Gandy, Vikas Saini, Daniel R. George, Eric B. Larson, G. Caleb Alexander, Jerry Avorn, Shannon Brownlee, Cameron Camp, Howard Chertkow, Adriane Fugh-Berman, Rob Howard, Aaron Kesselheim, Kenneth M. Langa, George Perry, Edo Richard, Lon Schneider

Summary: The FDA's controversial approval of aducanumab for Alzheimer's disease in June 2021 has raised significant concerns due to its lack of clinical efficacy evidence, safety issues, and high cost. In December 2021, an international group recommended the withdrawal of FDA approval for aducanumab, supporting the filing of a formal Citizen Petition by the Right Care Alliance.

JOURNAL OF ALZHEIMERS DISEASE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

α-Enolase reduces cerebrovascular Aβ deposits by protecting Aβ amyloid formation

Yasuteru Inoue, Masayoshi Tasaki, Teruaki Masuda, Yohei Misumi, Toshiya Nomura, Yukio Ando, Mitsuharu Ueda

Summary: In this study, the researchers found that α-enolase (ENO1) can interact with amyloid beta (Aβ) and inhibit its fibril formation. They also demonstrated that ENO1 can disrupt Aβ fibrils and weaken their cytotoxic effects by degrading Aβ peptides. Additionally, infusion of ENO1 into mouse brains reduced cerebrovascular Aβ deposits and improved cognitive impairment. These findings suggest that ENO1 may be a therapeutic target in cerebral amyloid angiopathy (CAA).

CELLULAR AND MOLECULAR LIFE SCIENCES (2022)

添加到收藏夹

Review Medicine, Research & Experimental

Aducanumab making a comeback in Alzheimer's disease: An old wine in a new bottle

Tapan Behl, Ishnoor Kaur, Aayush Sehgal, Sukhbir Singh, Neelam Sharma, Hafiz A. Makeen, Mohammed Albratty, Hassan A. Alhazmi, Shatha Ghazi Felemban, Amal M. Alsubayiel, Saurabh Bhatia, Simona Bungau

Summary: The article discusses the discovery of aducanumab as an antibody-based immunotherapy for Alzheimer's disease and the controversies surrounding its FDA approval. It explores the failure of anti-amyloid therapies in AD and the impact of aducanumab in AD models, as well as its potential implications.

BIOMEDICINE & PHARMACOTHERAPY (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Plasma Exchange Reduces Aβ Levels in Plasma and Decreases Amyloid Plaques in the Brain in a Mouse Model of Alzheimer's Disease

Santiago Ramirez, Suelyn Koerich, Natalia Astudillo, Nicole De Gregorio, Rabab Al-Lahham, Tyler Allison, Natalia Pessoa Rocha, Fei Wang, Claudio Soto

Summary: This study aimed to evaluate the effect of removing Aβ from blood plasma on the accumulation of amyloid plaques in the brain. The results showed a reduction in Aβ levels in the plasma and insoluble brain fractions, as well as a decrease in amyloid plaque burden and changes in plaque size distribution in the cortex and hippocampus. These findings support the importance of targeting Aβ in the periphery and suggest plasma exchange as a potential non-pharmacological strategy for slowing down AD pathogenesis.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Eugenitol ameliorates memory impairments in 5XFAD mice by reducing Aβ plaques and neuroinflammation

Eunbi Cho, Kumju Youn, Huiyoung Kwon, Jieun Jeon, Wan-Seob Cho, Se Jin Park, Seung Hwan Son, Dae Sik Jang, Chan Young Shin, Minho Moon, Mira Jun, Nam-Jung Kim, Dong Hyun Kim

Summary: This study investigated the effects of eugenitol in an AD mouse model and found that it inhibits the formation of A beta plaques and reduces neuronal cell death. In silico docking simulation showed that eugenitol may interact with A beta monomers and fibrils.

BIOMEDICINE & PHARMACOTHERAPY (2022)

添加到收藏夹

Review Biochemistry & Molecular Biology

Aducanumab and Its Effects on Tau Pathology: Is This the Turning Point of Amyloid Hypothesis?

Serena Silvestro, Andrea Valeri, Emanuela Mazzon

Summary: Alzheimer's disease is a neurodegenerative disorder with beta-amyloid plaques and neurofibrillary tangles of Tau proteins as its main pathological mechanisms. Aducanumab, a monoclonal antibody targeting A beta, has shown promising results in reducing Aβ accumulation and slowing cognitive impairment progression, potentially marking a milestone in the development of efficient drugs for AD.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

添加到收藏夹

Article Biotechnology & Applied Microbiology

Peripheral administration of nanomicelle-encapsulated anti-Aβ oligomer fragment antibody reduces various toxic Aβ species in the brain

Akiko Amano, Nobuo Sanjo, Wataru Araki, Yasutaka Anraku, Makoto Nakakido, Etsuro Matsubara, Takami Tomiyama, Tetsuya Nagata, Kouhei Tsumoto, Kazunori Kataoka, Takanori Yokota

Summary: Researchers developed polymeric nanomicelles capable of passing through the blood-brain barrier to deliver specific antibodies to the brain. The administration of 6H4 antibody fragments in polymeric nanomicelles for 10 weeks significantly reduced the amounts of toxic A beta species in the brain and inhibited the formation of A beta plaques. Behavioral analysis also showed an improvement in spatial reference memory in mice with Alzheimer's disease.

JOURNAL OF NANOBIOTECHNOLOGY (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Fast green FCF inhibits Aβ fibrillogenesis, disintegrates mature fibrils, reduces the cytotoxicity, and attenuates Aβ-induced cognitive impairment in mice

Fufeng Liu, Wenjuan Wang, Zhenquan Xuan, Luying Jiang, Beibei Chen, Qinchen Dong, Fang Zhao, Wei Cui, Li Li, Fuping Lu

Summary: This study found that Fast Green FCF (FGF) can effectively inhibit Aβ-induced neurotoxicity by reducing Aβ fibrillogenesis, disintegrating mature fibrils, decreasing Aβ-induced cytotoxicity, and improving Aβ-induced learning and memory impairments. Molecular dynamics simulations demonstrated that FGF can interact with Aβ through various mechanisms to reduce its neurotoxic effects.

INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES (2021)

添加到收藏夹

Article Geriatrics & Gerontology

Isoniazid improves cognitive performance, clears Aβ plaques, and protects dendritic synapses in APP/PS1 transgenic mice

Jiacheng Chen, Ning Guo, Yuting Ruan, Yingren Mai, Wang Liao, Yanqing Feng

Summary: This study found that isoniazid administration can effectively improve cognitive performance, clear Aβ plaques, protect dendritic synapses, and reduce innate immune cells around the Aβ plaques in a transgenic mouse model of Alzheimer's disease. These results suggest that isoniazid could be a potential drug for AD treatment.

FRONTIERS IN AGING NEUROSCIENCE (2023)

添加到收藏夹

Review Neurosciences

A Primer on the Evolution of Aducanumab: The First Antibody Approved for Treatment of Alzheimer's Disease

Sanchari Mukhopadhyay, Debanjan Banerjee

Summary: Alzheimer's disease is the most common form of dementia with the global burden projected to triple by 2050, yet treatment options are limited. Aducanumab, the first monoclonal antibody approved for mild AD, offers promise for the future. The approval of Aducanumab is based on its potential to reduce amyloid-beta load in the brain, despite global skepticism and hope surrounding its efficacy and implications.

JOURNAL OF ALZHEIMERS DISEASE (2021)

添加到收藏夹

Article Pharmacology & Pharmacy

Ginsenoside compound K reduces neuronal damage and improves neuronal synaptic dysfunction by targeting Aβ

Na Li, Qihang Pang, Yanhong Zhang, Jianan Lin, Hui Li, Zhen Li, Yaxin Liu, Xingyu Fang, Yu An, Haonan Bai, Dianyu Li, Zhanhong Cao, Jian Liu, Qing Yang, Shaodan Hu

Summary: The study found that Ginsenoside Compound K (CK) can bind to A beta, reduce its aggregation, and inhibit its accumulation in the extracellular space. CK also improves cognitive impairment and protects neurons by reducing oxidative damage and enhancing synaptic function through modulation of the Nrf2/Keap1 signaling pathway.

FRONTIERS IN PHARMACOLOGY (2023)

添加到收藏夹

Article Immunology

Astrocyte-specific knockout of YKL-40/Chi3l1 reduces Aβ burden and restores memory functions in 5xFAD mice

Xiaoyan Zeng, Stanley K. K. Cheung, Mengqi Shi, Penelope M. Y. Or, Zhining Li, Julia Y. H. Liu, Wayne L. H. Ho, Tian Liu, Kun Lu, John A. Rudd, Yubing Wang, Andrew M. Chan

Summary: This study found that increased expression of YKL-40 in astrocytes is associated with activated astrocytes in an Alzheimer's disease model. A beta 1-42 upregulates YKL-40 through the PI3-K signaling pathway in primary astrocytes, leading to synaptic degeneration and impaired neuronal function. Knockout of YKL-40 in astrocytes reduces amyloid plaque deposition, attenuates glial activation, reduces neuronal attrition, and restores memory function in symptomatic Alzheimer's disease mice.

JOURNAL OF NEUROINFLAMMATION (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Peptide aptamer targeting Aβ-PrP-Fyn axis reduces Alzheimer's disease pathologies in 5XFAD transgenic mouse model

Tahir Ali, Antonia N. N. Klein, Alex Vu, Maria I. I. Arifin, Samia Hannaoui, Sabine Gilch

Summary: Currently, there are no effective therapeutics for incurable neurodegenerative diseases such as Alzheimer's disease (AD). However, a peptide aptamer called PA8 has shown promise in targeting the AβO-PrP-Fyn axis and preventing associated pathologies. In vitro experiments demonstrated that PA8 prevented the binding of AβO to PrPC and reduced neurotoxicity in neurons. In vivo experiments using a transgenic mouse model of AD showed that treatment with PA8 improved learning and memory functions, reduced AβO levels and plaques, and decreased downstream signaling in the brain tissue.

CELLULAR AND MOLECULAR LIFE SCIENCES (2023)

添加到收藏夹

Article Medicine, Research & Experimental

A mathematical model on Aβ blood-brain transport: Simulations of plaques' formation in Alzheimer's disease

Eleonora Ficiara, Ilaria Stura, Caterina Guiot, Ezio Venturino

Summary: The study investigates the transport and accumulation of toxic substance Aβ in the blood-brain barrier and brain in Alzheimer's disease. By performing a sensitivity analysis, the important parameters that potentially affect pathological conditions are identified.

MEDICAL HYPOTHESES (2023)

添加到收藏夹

Article Clinical Neurology

Fumarates modulate microglia activation through a novel HCAR2 signaling pathway and rescue synaptic dysregulation in inflamed CNS

Benedetta Parodi, Silvia Rossi, Sara Morando, Christian Cordano, Alberto Bragoni, Caterina Motta, Cesare Usai, Brian T. Wipke, Robert H. Scannevin, Giovanni L. Mancardi, Diego Centonze, Nicole Kerlero de Rosbo, Antonio Uccelli

ACTA NEUROPATHOLOGICA (2015)

添加到收藏夹

Article Biochemistry & Molecular Biology

Pharmacodynamics of Dimethyl Fumarate Are Tissue Specific and Involve NRF2-Dependent and -Independent Mechanisms

Melanie S. Brennan, Hiral Patel, Norm Allaire, Alice Thai, Patrick Cullen, Sarah Ryan, Matvey Lukashev, Pradeep Bista, Ron Huang, Kenneth J. Rhodes, Robert H. Scannevin

ANTIOXIDANTS & REDOX SIGNALING (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Repurposing the NRF2 Activator Dimethyl Fumarate as Therapy Against Synucleinopathy in Parkinson's Disease

Isabel Lastres-Becker, Angel J. Garcia-Yague, Robert H. Scannevin, Maria J. Casarejos, Sebastian Kuegler, Alberto Rabano, Antonio Cuadrado

ANTIOXIDANTS & REDOX SIGNALING (2016)

添加到收藏夹

Article Immunology

Dimethyl fumarate alters microglia phenotype and protects neurons against proinflammatory toxic microenvironments

Haiyan Peng, Huo Li, Adam Sheehy, Patrick Cullen, Norm Allaire, Robert H. Scannevin

JOURNAL OF NEUROIMMUNOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

The antibody aducanumab reduces Aβ plaques in Alzheimer's disease

Jeff Sevigny, Ping Chiao, Thierry Bussiere, Paul H. Weinreb, Leslie Williams, Marcel Maier, Robert Dunstan, Stephen Salloway, Tianle Chen, Yan Ling, John O'Gorman, Fang Qian, Mahin Arastu, Mingwei Li, Sowmya Chollate, Melanie S. Brennan, Omar Quintero-Monzon, Robert H. Scannevin, H. Moore Arnold, Thomas Engber, Kenneth Rhodes, James Ferrero, Yaming Hang, Alvydas Mikulskis, Jan Grimm, Christoph Hock, Roger M. Nitsch, Alfred Sandrock

NATURE (2016)

添加到收藏夹

Article Neurosciences

BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease

Robert H. Scannevin, Sowmya Chollate, Melanie S. Brennan, Pamela A. Snodgrass-Belt, Hairuo Peng, Lin Xu, Mi-young Jung, Thierry Bussiere, Mahin F. Arastu, Tina Talreja, Zhili Xin, Robert W. Dunstan, Diana Fahrer, Ellen Rohde, Anthone W. Dunah, Joy Wang, Gnanasambandam Kumaravel, Arthur G. Taveras, H. Moore Arnold, Kenneth J. Rhodes

NEUROPHARMACOLOGY (2016)

添加到收藏夹

Article Multidisciplinary Sciences

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2

Ulf Schulze-Topphoff, Michel Varrin-Doyer, Kara Pekarek, Collin M. Spencer, Aparna Shetty, Sharon A. Sagan, Bruce A. C. Cree, Raymond A. Sobel, Brian T. Wipke, Lawrence Steinman, Robert H. Scannevin, Scott S. Zamvil

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)

添加到收藏夹

Article Biochemistry & Molecular Biology

Discovery of a highly selective chemical inhibitor of matrix metalloproteinase-9 (MMP-9) that allosterically inhibits zymogen activation

Robert H. Scannevin, Richard Alexander, Tara Mezzasalma Haarlander, Sharon L. Burke, Monica Singer, Cuifen Huo, Yue-Mei Zhang, Diane Maguire, John Spurlino, Ingrid Deckman, Karen I. Carroll, Frank Lewandowski, Eric Devine, Keli Dzordzorme, Brett Tounge, Cindy Milligan, Shariff Bayoumy, Robyn Williams, Celine Schalk-Hihi, Kristi Leonard, Paul Jackson, Matthew Todd, Lawrence C. Kuo, Kenneth J. Rhodes

JOURNAL OF BIOLOGICAL CHEMISTRY (2017)

添加到收藏夹

Article Endocrinology & Metabolism

Dimethyl fumarate improves white matter function following severe hypoperfusion: Involvement of microglia/macrophages and inflammatory mediators

Jill H. Fowler, Jamie McQueen, Philip R. Holland, Yasmina Manso, Martina Marangoni, Fiona Scott, Emma Chisholm, Robert H. Scannevin, Giles E. Hardingham, Karen Horsburgh

JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2018)

添加到收藏夹

Review Biochemistry & Molecular Biology

Therapeutic strategies for targeting neurodegenerative protein misfolding disorders

Robert H. Scannevin

CURRENT OPINION IN CHEMICAL BIOLOGY (2018)

添加到收藏夹

Article Multidisciplinary Sciences

The NRF2 transcriptional target, OSGIN1, contributes to monomethyl fumarate-mediated cytoprotection in human astrocytes

Melanie S. Brennan, Maria F. Matos, Karl E. Richter, Bing Li, Robert H. Scannevin

SCIENTIFIC REPORTS (2017)

添加到收藏夹

Article Multidisciplinary Sciences

Potent PDZ-Domain PICK1 Inhibitors that Modulate Amyloid Beta-Mediated Synaptic Dysfunction

Edward Y. S. Lin, Laura F. Silvian, Douglas J. Marcotte, Charles C. Banos, Flora Jow, Timothy R. Chan, Robert M. Arduini, Fang Qian, Darren P. Baker, Chris Bergeron, Catherine A. Hession, Richard L. Huganir, Cassandra F. Borenstein, Istvan Enyedy, Jinming Zou, Ellen Rohde, Marion Wittmann, Gnanasambandam Kumaravel, Kenneth J. Rhodes, Robert H. Scannevin, AnthoneW. Dunah, Kevin M. Guckian

SCIENTIFIC REPORTS (2018)

添加到收藏夹

Article Cell Biology

Inhibiting Stearoyl-CoA Desaturase Ameliorates α-Synuclein Cytotoxicity

Benjamin M. Vincent, Daniel F. Tardiff, Jeff S. Piotrowski, Rebecca Aron, Matthew C. Lucas, Chee Yeun Chung, Helene Bacherman, YiQun Chen, Michelle Pires, Radha Subramaniam, Dimple B. Doshi, Heather Sadlish, Waseem K. Raja, Eric J. Solis, Vikram Khurana, Bertrand Le Bourdonnec, Robert H. Scannevin, Kenneth J. Rhodes

CELL REPORTS (2018)

添加到收藏夹

Article Clinical Neurology

Dimethyl fumarate impairs differentiated B cells and fosters central nervous system integrity in treatment of multiple sclerosis

Jan Traub, Sarah Traffehn, Jasmin Ochs, Silke Haeusser-Kinzel, Schirin Stephan, Robert Scannevin, Wolfgang Brueck, Inke Metz, Martin S. Weber

BRAIN PATHOLOGY (2019)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.